Singapore markets closed

Pyxis Oncology, Inc. (PYXS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.4500-0.0500 (-1.11%)
At close: 04:00PM EDT
4.4000 -0.05 (-1.12%)
Pre-market: 08:21AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.5000
Open4.5100
Bid4.4200 x 400
Ask4.4800 x 500
Day's range4.3800 - 4.6300
52-week range1.3500 - 6.8500
Volume233,470
Avg. volume908,293
Market cap258.694M
Beta (5Y monthly)1.51
PE ratio (TTM)N/A
EPS (TTM)-1.8500
Earnings date11 May 2024 - 15 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.00
  • GlobeNewswire

    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 39,680 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 49,600 shares of Pyxis Oncology’s common stock to a newly hired

  • GlobeNewswire

    Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

    Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rig

  • GuruFocus.com

    Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges

    Financial Results for Q4 and Full Year 2023 Highlight Key Developments and Future Outlook